Multivariable analysis of factors associated with mortality in patients with type 2 diabetes and COVID-19 treated with sitagliptin or with standard-of-care therapy
| OR (95% CI) | P value | |
|---|---|---|
| Treatment with sitagliptin | 0.23 (0.12–0.46) | 0.0001 |
| Sex (male) | 1.05 (0.51–2.16) | 0.88 |
| Age (years) | 1.07 (1.04–1.11) | 0.0001 |
| Cancer | 1.74 (0.78–3.88) | 0.17 |
| Cardiovascular disease | 2.5 (1.30–4.81) | 0.006 |
| Chronic kidney disease | 1.12 (0.54–2.35) | 0.74 |
| Use of hydroxychloroquine | 1.47 (0.55–3.87) | 0.43 |
| Use of antiviral agents | 0.91 (0.44–1.85) | 0.79 |